Aethlon Medical, Inc. (OTCMKTS:AEMD) Continues To Slip

[[tagnumber 0]][[tagnumber 1]]Aethlon Medical, Inc. (OTCMKTS:AEMD) had a great run over the past 2 months and ran from a price of around $0.12 per share in the beginning of October to over $0.50 in the end of November driven by Ebola hype.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]More recently, however, the ticker has been having a much less attractive performance and has closed all the sessions of this month, apart from December first, in the red, losing a total of more than 40% of its value as of the end of last week.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]There are several reasons for which the stock couldn’t continue its ascent up the charts for much longer. One of them was the fact that the financials that [[tagnumber 10]]AEMD [[tagnumber 11]]had to show for the third quarter of the year couldn’t exactly back up a market cap of over $160 million, which the ticker had on December 1.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Here are some of the numbers of prime interest contained in the balance sheet of the aforementioned filing.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 19]] [[tagnumber 20]]cash: $526 thousand[[tagnumber 21]] [[tagnumber 20]]current assets: $892 thousand[[tagnumber 21]] [[tagnumber 20]]total assets: $1 million[[tagnumber 21]] [[tagnumber 20]]current liabilities: $3.38 million[[tagnumber 21]] [[tagnumber 20]]total liabilities: $4.37 million[[tagnumber 21]] [[tagnumber 20]]quarterly revenues: $479 thousand[[tagnumber 21]] [[tagnumber 20]]operating loss: $601 thousand[[tagnumber 21]] [[tagnumber 34]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]And if the market cap didn’t reflect the book value of [[tagnumber 10]]AEMD [[tagnumber 11]]there was something far worse that could happen and cripple the company stock. As we wrote in our previous article, [[tagnumber 10]]AEMD [[tagnumber 11]]informed the public through a press release and an 8–K filing in the end of last month that they have sold 11 million shares of common stock and 13.2 million warrants that are exercisable at $0.30 each for a total of $3.3 million.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This is not the first time that the company issues heavily discounted shares. Between March 31 and November 7 the outstanding share count of [[tagnumber 10]]AEMD [[tagnumber 11]]went up from 225 million to more than 295 million. A large portion of the stock that saw the light of day in that period was issued at prices that were sometimes just $0.05 per share.[[tagnumber 48]][[tagnumber 49]][[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Furthermore, the press release with which the company informed us of the shipment of Hemopurifier® units to the Nebraska Medical Center(NMC) seems to have been a bit over the top as suggested by The Street writer Adam Feuerstein who contacted NMC’s spokesman Taylor Wilson to ask him about confirmation of [[tagnumber 10]]AEMD’s [[tagnumber 11]]claim to which he received the following answer – “[[tagnumber 56]]They [the Hemopurifier units] may have been shipped, but we have not decided whether to use them or if they are effective. Essentially, they sent them to us, but we have had very little involvement beyond that[[tagnumber 57]],“[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In any case, the ticker is still sliding down the charts and it even seems that it is picking up downward momentum as it closed Friday’s session with a 23.77% loss, dropping to $0.295 per share while the total amount of traded stock generated $7.71 million in dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Only time will tell if [[tagnumber 10]]AEMD [[tagnumber 11]]can regain value, but one thing is for sure – it is imperative to always do your due diligence and weigh out the risks before putting any money on the line. [[tagnumber 2]]